← 治験一覧に戻る
喘息患者におけるデュピルマブの長期安全性評価（LIBERTY ASTHMA TRAVERSE）
基本情報
- NCT ID
- NCT02134028
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 2,282
- 治験依頼者名
- Sanofi
概要
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691). Secondary Objectives: To evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study. To evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to: * Systemic exposure * Anti-drug antibodies * Biomarkers
対象疾患
Asthma
介入
Dupilumab(DRUG)